Pfizer Moving to 3-Dose Trial for Kids After 2-Shot Vaccine Fails
Pfizer-BioNTech announced Friday its two-shot vaccine didn’t perform adequately in children ages 2 to 5 years old, and it will test a three-dose series for official authorization.
The pharmaceutical companies said they will expand ongoing clinical trials of their COVID-19 vaccine in children to include a third dose for participants as young as 6 months old, NPR reported. . .
The decision, the companies said, was made “following a routine review by the external independent Data Monitoring Committee,” which acts as a watchdog over the clinical trials.
They insisted, however, that no “safety concerns” were identified, and the 3 microgram doses “demonstrated a favorable safety profile in children 6 months to under 5 years of age.”
The FDA has authorized the Pfizer-BioNTech vaccine only for emergency use in children aged 5 and older. Adults get 30 micrograms of the Pfizer shot per dose, and children ages 5 to 11 get 10 micrograms. In November, the FDA authorized a third booster dose for all U.S. adults. (Read more from “Pfizer Moving to 3-Dose Trial for Kids After 2-Shot Vaccine Fails” HERE)
Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.
